Status:

COMPLETED

Preemptive Treatment With XONRID to Reduce Radiation Induced Dermatitis in Head and Neck Cancer Patients

Lead Sponsor:

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Conditions:

Head and Neck Cancer

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

There is a strong need to study products with a preemptive role in radiation dermatitis development, with a trial design taking in account patient subjective evaluation and compliance. XONRID is a pr...

Detailed Description

The patients will be treated with XONRID + standard of care (SOC) preemptive treatment adopted during radiation treatment for head and neck cancer patients in the Institution. Patients will be planne...

Eligibility Criteria

Inclusion

  • \> 18 years
  • Performance status \< 2
  • Epithelial carcinoma of oropharynx, nasopharynx, larynx, hypopharynx, paranasal sinus and salivary glands
  • Planned to receive at least 50 Gy on one side of the neck with at least the 2nd level of neck nodes irradiated
  • Postoperative or curative radiation treatment
  • Concurrent platinum based chemotherapy is accepted, but not mandatory
  • Conventional fractionation (1.8-2.12 GY per fraction, one daily fraction, 5 fractions a week )

Exclusion

  • Pregnant or lactating women
  • Planned to receive concurrent cetuximab
  • Previous radiation therapy on the head and neck area
  • Cutaneous and connettive diseases (i.e. lupus erythematosus or scleroderma)
  • Systemic diseases known to delay the skin healing process such as diabetes mellitus or severe renal failure.
  • Use of a tissue-equivalent bolus
  • Use of over-the-counter topical medications containing steroids
  • Presence of rashes or unhealed wounds in the radiation field
  • Recent sun exposure
  • Mental conditions that could adversely affect patients' adherence to the study

Key Trial Info

Start Date :

January 1 2015

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2019

Estimated Enrollment :

80 Patients enrolled

Trial Details

Trial ID

NCT02261181

Start Date

January 1 2015

End Date

January 1 2019

Last Update

September 29 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Fondazione IRCCS Istituto Nazionale Tumori

Milan, Italy, 20133